Nature Reviews Drug Discovery最新文献_第3页

Open Targets: 10 years of partnership in target discovery 开放目标：在目标发现方面的10年合作伙伴关系

Nature Reviews Drug Discovery Pub Date : 2024-12-17 DOI: 10.1038/d41573-024-00204-2

David G. Hulcoop, Gosia Trynka, Ellen M. McDonagh

引用次数: 0

IRDiRC perspectives on the application of digital biomarkers in therapeutic development for rare diseases IRDiRC 关于在罕见病治疗开发中应用数字生物标记的观点

Nature Reviews Drug Discovery Pub Date : 2024-12-16 DOI: 10.1038/d41573-024-00196-z

Rajesh Krishna, Anneliene H. Jonker, Thomas Morel, Ken Sakushima, Anna M. G. Pasmooij, Daniel O’Connor

引用次数: 0

Harnessing the biology of regulatory T cells to treat disease 利用调节性T细胞的生物学特性来治疗疾病

Nature Reviews Drug Discovery Pub Date : 2024-12-16 DOI: 10.1038/s41573-024-01089-x

Christine M. Wardell, Dominic A. Boardman, Megan K. Levings

{"title":"Harnessing the biology of regulatory T cells to treat disease","authors":"Christine M. Wardell, Dominic A. Boardman, Megan K. Levings","doi":"10.1038/s41573-024-01089-x","DOIUrl":"https://doi.org/10.1038/s41573-024-01089-x","url":null,"abstract":"Regulatory T (Treg) cells are a suppressive subset of CD4+ T cells that maintain immune homeostasis and restrain inflammation. Three decades after their discovery, the promise of strategies to harness Treg cells for therapy has never been stronger. Multiple clinical trials seeking to enhance endogenous Treg cells or deliver them as a cell-based therapy have been performed and hint at signs of success, as well as to important limitations and unanswered questions. Strategies to deplete Treg cells in cancer are also in active clinical testing. Furthermore, multi-dimensional methods to interrogate the biology of Treg cells are leading to a refined understanding of Treg cell biology and new approaches to harness tissue-specific functions for therapy. A new generation of Treg cell clinical trials is now being fuelled by advances in nanomedicine and synthetic biology, seeking more precise ways to tailor Treg cell function. This Review will discuss recent advances in our understanding of human Treg cell biology, with a focus on mechanisms of action and strategies to assess outcomes of Treg cell-targeted therapies. It highlights results from recent clinical trials aiming to enhance or inhibit Treg cell activity in a variety of diseases, including allergy, transplantation, autoimmunity and cancer, and discusses ongoing strategies to refine these approaches.","PeriodicalId":18847,"journal":{"name":"Nature Reviews Drug Discovery","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142825691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting metabolic dysfunction of CD8 T cells and natural killer cells in cancer 靶向CD8 T细胞和自然杀伤细胞在肿瘤中的代谢功能障碍

Nature Reviews Drug Discovery Pub Date : 2024-12-12 DOI: 10.1038/s41573-024-01098-w

Sébastien Viel, Eric Vivier, Thierry Walzer, Antoine Marçais

引用次数: 0

Vaccines for cancer prevention: exploring opportunities and navigating challenges 预防癌症的疫苗：探索机遇和应对挑战

Nature Reviews Drug Discovery Pub Date : 2024-12-02 DOI: 10.1038/s41573-024-01081-5

Michele Graciotti, Lana E. Kandalaft

{"title":"Vaccines for cancer prevention: exploring opportunities and navigating challenges","authors":"Michele Graciotti, Lana E. Kandalaft","doi":"10.1038/s41573-024-01081-5","DOIUrl":"https://doi.org/10.1038/s41573-024-01081-5","url":null,"abstract":"Improved understanding of cancer immunology has gradually brought increasing attention towards cancer-preventive vaccines as an important tool in the fight against cancer. The aim of this approach is to reduce cancer occurrence by inducing a specific immune response targeting tumours at an early stage before they can fully develop. The great advantage of preventive cancer vaccines lies in the potential to harness a less-compromised immune system in vaccine recipients before their immune responses become affected by the advanced status of the disease itself or by aggressive treatments such as chemotherapy. Successful implementation of immunoprevention against oncogenic viruses such as hepatitis B and papillomavirus has led to a dramatic decrease in virally induced cancers. Extending this approach to other cancers holds great promise but remains a major challenge. Here, we provide a comprehensive review of preclinical evidence supporting this approach, encouraging results from pioneering clinical studies as well as a discussion on the key aspects and open questions to address in order to design potent prophylactic cancer vaccines in the near future.","PeriodicalId":18847,"journal":{"name":"Nature Reviews Drug Discovery","volume":"24 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142760023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antiviral target compound profile for pandemic preparedness 大流行防范的抗病毒靶标化合物概况

Nature Reviews Drug Discovery Pub Date : 2024-12-02 DOI: 10.1038/s41573-024-01102-3

James F. Demarest, Ruxandra Draghia-Akli, Tomas Cihlar, Kenneth Bradley, John A. T. Young, Richa Chandra, Sujata Vaidyanathan, Margaret Chu-Moyer, Christopher L. Lynch, Andrew Campbell, Kumar Singh Saikatendu, John P. Bilello, Yoshihiko Murata, Marnix van Loock, Aeron C. Hurt, Timothy Tellinghuisen, Lee Ruggiero, Richard Mackman, Nina M. Hill, John C. Pottage

引用次数: 0

Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH) 代谢功能障碍相关性脂肪性肝炎（MASH）的治疗前景

Nature Reviews Drug Discovery Pub Date : 2024-11-28 DOI: 10.1038/s41573-024-01084-2

Albert Do, Frhaan Zahrawi, Wajahat Z. Mehal

{"title":"Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)","authors":"Albert Do, Frhaan Zahrawi, Wajahat Z. Mehal","doi":"10.1038/s41573-024-01084-2","DOIUrl":"https://doi.org/10.1038/s41573-024-01084-2","url":null,"abstract":"Metabolic dysfunction-associated steatotic liver disease (MASLD) and its severe subgroup metabolic dysfunction-associated steatohepatitis (MASH) have become a global epidemic and are driven by chronic overnutrition and multiple genetic susceptibility factors. The physiological outcomes include hepatocyte death, liver inflammation and cirrhosis. The first therapeutic for MASLD and MASH, resmetirom, has recently been approved for clinical use and has energized this therapeutic space. However, there is still much to learn in clinical studies of MASH, such as the scale of placebo responses, optimal trial end points, the time required for fibrosis reversal and side effect profiles. This Review introduces aspects of disease pathogenesis related to drug development and discusses two main therapeutic approaches. Thyroid hormone receptor-β agonists, such as resmetirom, as well as fatty acid synthase inhibitors, target the liver and enable it to function within a toxic metabolic environment. In parallel, incretin analogues such as semaglutide improve metabolism, allowing the liver to self-regulate and reversing many aspects of MASH. We also discuss how combinations of therapeutics could potentially be used to treat patients.","PeriodicalId":18847,"journal":{"name":"Nature Reviews Drug Discovery","volume":"7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142735838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The targeted protein degradation landscape 靶向蛋白质降解情况

Nature Reviews Drug Discovery Pub Date : 2024-11-27 DOI: 10.1038/d41573-024-00187-0

引用次数: 0

Targeting lysine acetylation readers and writers 瞄准赖氨酸乙酰化的读者和作者

Nature Reviews Drug Discovery Pub Date : 2024-11-21 DOI: 10.1038/s41573-024-01080-6

Ming-Ming Zhou, Philip A. Cole

引用次数: 0

The benefits of translating biomedical research at drug discovery institutes 药物研发机构转化生物医学研究的益处

Nature Reviews Drug Discovery Pub Date : 2024-09-26 DOI: 10.1038/d41573-024-00142-z

David J. Huggins, Jonathan Baell, Paul E. Brennan, Alex Burgin, Duncan E. Scott

引用次数: 0